

Ref. No:	1873
Date:	03/07/25
Subject:	Diffuse Large B Cell Lymphoma (DLBCL)

REQUEST

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
- (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)
- R-GemOX (rituximab, gemcitabine and oxaliplatin)
- Axicabtagene ciloleucel
- Tisagenlecleucel
- Epcoritamab
- Loncastuximab tesirine
- Glofitamab

- Any other SACT
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- R-GemOX (rituximab, gemcitabine and oxaliplatin)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatments

RESPONSE

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

13

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

10

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - **17**
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - **0**
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - **0**
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) - **<5**

- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) - **0**
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) - **0**
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) - **<5**
- (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) - **0**
- R-GemOX (rituximab, gemcitabine and oxaliplatin) - **0**
- Axicabtagene ciloleucel - **0**
- Tisagenlecleucel - **0**
- Epcoritamab - **0**
- Loncastuximab tesirine - **0**
- Glofitamab - **0**
- Any other SACT - **<5**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta) -**0**
- Tisagenlecleucel - **0**
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - **0**
- R-GemOX (rituximab, gemcitabine and oxaliplatin) - **0**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**
- Any other treatments -**0**